Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545628 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL1654271 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL3547165 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL18244613 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL3542040 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL3541625 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL102373 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL21877046 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL21876707 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 | |
| SCHEMBL31074305 | 1.00 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22HSD17B10CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606800-A1 | COMPOUND BASED ON ORYDALMINE STRUCTURE AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025064681-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-118557747-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2024172341-A1 | QUANTUM DOT, METHOD FOR PREPARING QUANTUM DOT, QUANTUM DOT COMPOSITION, AND ELECTRONIC DEVICE | 덕산네오룩스 주식회사 | 2024-08-22 | — | — | WO | disclosed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-113423430-A | Amanitoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| US-8173198-B2 | Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers | Life Technologies Corporation (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110159305-A1 | Intermediates And Methods For Forming Passivated Surfaces On Oxide Layers And Articles Produced Thereby | APPLIED BIOSYSTEMS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110159305-A1 | Intermediates And Methods For Forming Passivated Surfaces On Oxide Layers And Articles Produced Thereby | APPLIED BIOSYSTEMS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-7928038-B2 | Intermediates and methods for forming passivated surfaces on oxide layers and articles produced thereby | APPLIED BIOSYSTEMS, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928038-B2 | Intermediates and methods for forming passivated surfaces on oxide layers and articles produced thereby | APPLIED BIOSYSTEMS, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2011038158-A2 | METHODS, COMPOSITIONS, SYSTEMS AND APPARATUS FOR MOLECULAR ARRAY FABRICATION | Life Technologies Corporation (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100086927-A1 | DEPOSITION OF METAL OXIDES ONTO SURFACES AS AN IMMOBILIZATION VEHICLE FOR CARBOXYLATED OR PHOPHATED PARTICLES OR POLYMERS | Life Technologies Corporation (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100086927-A1 | DEPOSITION OF METAL OXIDES ONTO SURFACES AS AN IMMOBILIZATION VEHICLE FOR CARBOXYLATED OR PHOPHATED PARTICLES OR POLYMERS | Life Technologies Corporation (US) | 2010-04-08 | — | — | US | disclosed |
| US-20080176761-A1 | Intermediates and Methods for Forming Passivated Surfaces on Oxide Layers and Articles Produced Thereby | APPLERA CORPORATION, APPLIED BIOSYSTEMS GROUP (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176761-A1 | Intermediates and Methods for Forming Passivated Surfaces on Oxide Layers and Articles Produced Thereby | APPLERA CORPORATION, APPLIED BIOSYSTEMS GROUP (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | ALDH1A1 60/4885BLM 3939/4885PMP22 3666/4885 |
| US-20080176761-A1 | Intermediates and Methods for Forming Passivated Surfaces on Oxide Layers and Articles Produced Thereby | POLM, SELP, POLH | ALDH1A1 2951/4885BLM 262/4885PMP22 2419/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | ALDH1A1 2397/4885BLM 2143/4885PMP22 1673/4885 |
| US-20100086927-A1 | DEPOSITION OF METAL OXIDES ONTO SURFACES AS AN IMMOBILIZATION VEHICLE FOR CARBOXYLATED OR PHOPHATED PARTICLES OR POLYMERS | POLM, POLH, POLQ | ALDH1A1 3377/4885BLM 1144/4885PMP22 2703/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | ALDH1A1 3405/4885BLM 219/4885PMP22 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.